We have also today published a new discussion aid to support shared decision making about HRT, focusing on the key risks and benefits to consider. The guideline clarifies that whilst HRT has some ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology being ...

The evaluation committee considered evidence submitted by Blueprint Medicines, a review of this submission by the external assessment group (EAG) and responses from stakeholders. See the committee ...

Review and download supporting evidence. Includes the full guideline if available.

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

A list of downloadable documents created during development.

Avapritinib (Ayvakyt) is indicated 'as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated haematological neoplasm (SM ...

Avapritinib (Ayvakyt) is available on the NHS. It is a possible treatment for advanced systemic mastocytosis (including aggressive systemic mastocytosis, systemic mastocytosis with an associated ...